Inclusion Criteria:

- Participant has a locally advanced or metastatic solid tumor for which carboplatin,
carboplatin/paclitaxel, or carboplatin/liposomal doxorubicin are the standard of
care.

- Participant has a performance status of 0 or 1 on the Eastern Cooperative Oncology
Group (ECOG) Performance Scale.

Exclusion Criteria:

- Participant has had chemotherapy, radiotherapy, or biological therapy within 4 weeks
prior to entering the study.

- Participant has had more than two prior lines of chemotherapy.

- Participant has known central nervous system metastases or a primary central nervous
system tumor.

- Participant is pregnant or breastfeeding or expecting to conceive during the
timeframe of the study.

- Participant is known to be human immunodeficiency virus (HIV) positive.

- Participant has a history of Hepatitis B or C.

- Participant has a symptomatic pleural effusion.

- Participant with a left ventricular ejection fraction (LVEF) below the institutional
norm, or with prior exposure to doxorubicin is not eligible for the MK4827 +
carboplatin/liposomal doxorubicin study arm.